Stay current with MiRXES
Newsroom > Media Releases
MiRXES announces appointment of Dan Headon as Senior Vice President, Marketing
SINGAPORE, 15 November 2021 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests, announced today the appointment of Mr. Dan HEADON as Senior Vice President (SVP), Marketing. Mr. Headon will raise the awareness of MiRXES’s products to patients and customers by partnering closely with the Product, Commercial Operations and Medical Affairs’ teams in launching new products and refining the marketing strategy for MiRXES’s existing products. Based in Australia, Mr. Headon will report to MiRXES’s Co-founder and CEO, Dr. Lihan ZHOU.
“With Dan’s demonstrable skills in leadership, business strategy, marketing, business development and sales, and a proven track record of developing functions and business across diverse geographies, I am confident that MiRXES will benefit greatly from his diverse marketing and industry experience,” said Dr. Zhou. “We are delighted to have Dan join the talented team at MiRXES to develop the marketing function and implement an integrated marketing planning process to serve both Asia Pacific and global markets. The team will plan and execute product launches and marketing programs, leveraging market intelligence and our strong product pipeline, to drive MiRXES’s next phase of growth.”
Mr. Headon brings with him more than 30 years of extensive experience in the biotechnology sector working for companies such as Biotech Australia, Millipore, Applied Biosystems and Illumina. Prior to joining MiRXES, he was the Director of Marketing for APAC at Illumina from 2008 to 2017, where he scaled the APAC marketing function from three to over 50 staff over a period of 10 years and contributed towards Illumina’s revenue growth in the region from USD 30 million per annum to over USD 500 million through a series of innovative marketing strategies.
Apart from Illumina, Mr. Headon also had a long stint with Applied Biosystems for 14 years, starting his career in sales, and then moved through various roles in product management and marketing management, as Divisional Business Director, Applied Markets Division and Marketing Director for East Asia, China & Oceania. He led the regional launches and ongoing marketing strategies for several technological advancements, including several automated DNA sequencing platforms (from slab gel, to capillary, to NGS), real-time PCR, bead-array based genotyping and the implementation of DNA in forensics.
Mr. Headon said, “I am thrilled to join MiRXES at this exciting point of its journey to save and improve lives. I look forward to leveraging my marketing experience in biotechnology to enable MiRXES to connect with patients and customers via innovative marketing strategies, as we continue to discover, develop and deliver accurate and accessible preventive healthcare solutions to all.”
Mr. Headon holds a Bachelor of Science degree from Macquarie University and a Graduate Diploma of Marketing from Monash University.
Founded in 2014 as a spin-off from Singapore’s Agency for Science, Technology, and Research (A*STAR) with strong support from the National University of Singapore (NUS), MiRXES is a leading developer of RNA-powered tests for disease early detection, with strong pipelines in multiple cancer types, as well as in cardiovascular, metabolic and infectious diseases. MiRXES is headquartered in Singapore, with operations in China, Japan and the United States, as well as commercial activities in over 45 countries globally. In 2019, MiRXES launched GASTROClear, the world’s first microRNA blood test for early detection of gastric cancer. The MiRXES’s multi-cancer early detection pipeline includes screening tests for lung, colorectal, liver, and breast cancer. In response to the COVID-19 pandemic in 2020, MiRXES worked closely with A*STAR, Diagnostics Development Hub (DxD) and Tan Tock Seng Hospital (TTSH) to mass produce Fortitude Kit, Singapore’s first authorized COVID-19 RT-PCR test. Since February 2020, more than 8 million Fortitude Kits have been deployed globally.
For more information, visit www.mirxes.com
Follow us on LinkedIn @ https://www.linkedin.com/company/mirxes/